Sanofi India Limited files SEBI Regulation 74(5) Certificate for period ended March 31, 2026
Sanofi India Limited has filed a certificate under SEBI Regulation 74(5) for the period ending March 31, 2026. The RTA, MUFG Intime India Private Limited, confirmed the processing of dematerialised securities. This is a routine compliance filing.
This is a standard compliance filing related to share transfer and dematerialisation processes, which is a routine operational activity for listed companies. It does not introduce any new business information or financial performance data that would significantly impact the company's stock or market perception.
The announcement is a routine regulatory filing regarding the confirmation of dematerialised securities and does not contain any material financial or business updates that would impact the company's sentiment.
Sanofi India Limited has submitted a certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. This certificate pertains to the period ended March 31, 2026.
The certificate was provided by MUFG Intime India Private Limited, the company's Registrar and Share Transfer Agent (RTA). MUFG Intime India Private Limited confirmed that securities received from depository participants for dematerialisation during the quarter ended March 31, 2026, were processed and listed on the stock exchanges. The security certificates received for dematerialisation were mutilated and cancelled after verification, and the depositories' names were substituted in the register of members within the prescribed timelines.
The company has requested that this certificate be taken on record by the stock exchanges.
What to do with a filing like this
Sanofi India Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sanofi India Limited. Read the original for the full detail.